Form 10-Q REXAHN PHARMACEUTICALS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Form 10-Q REXAHN PHARMACEUTICALS, For: Jun 30
August 14, 2014 9:45 AM EDT
Roth Capital maintains Rexahn Pharmaceuticals (AMEX: RNN) at Buy with a price target of $3 following the company's Q2 results and pipeline update.
Analyst Joseph Pantginis commented, The financial results currently do not impact our investment case. The... More
August 14, 2014 9:04 AM EDT
Rexahn Pharmaceuticals (AMEX: RNN) reported Q2 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02).
Pipeline Update:
Supinoxin (RX-5902)
In August 2013, Rexahn initiated a Phase I dose-escalation study of Supinoxin designed to evaluate the safety, tolerability, dose-limiting toxicities and maximal tolerated dose (MTD) in cancer patients with solid tumors that have previously failed treatment with approved therapies. Secondary endpoints include pharmacokinetic analysis and evaluating the preliminary anti-tumor effects of Supinoxin. In July, Rexahn announced that four dose groups (25, 50, 100 and 150 mg) had... More
